21 completed, 11 recruiting, 6 active not recruiting, 3 not yet recruiting. 8 Phase 1, 7 Phase 3, 5 Phase 2, 4 Phase 4, 3 Not applicable.
Follow MYK-461: new trials by email Literature Review of MYK-461 trials Research Report on MYK-461
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy Mavacamten - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Not yet recruiting | Bristol-Myers Squibb | 800 | 2026-09-30 | 2026-09-29 | |
| Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Mavacamten - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Phase 4 | Not yet recruiting | Second Affiliated Hospital of Nanchang University | 115 | 2026-09-01 | 2026-09-08 |
| Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial Camzyos (Mavacamten) - Hypertrophic Obstructive Cardiomyopathy \(HOCM\), Left Ventricular Outflow Tract Obstruction | Not applicable | Recruiting | University of Manchester | 75 | 2026-03-26 | 2026-05-22 |
| The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction mavacamten, Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol, diltiazem - Hypertrophic Cardiomyopathy (HCM) | Phase 4 | Enrolling by invitation | Second Affiliated Hospital, Zhejiang University, School of Medicine | 132 | 2026-03-01 | 2026-09-15 |
| Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM) Mavacamten - Cardiomyopathy | Recruiting | Bristol-Myers Squibb | 36 | 2026-02-05 | 2026-06-26 | |
| Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US Mavacamten - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Recruiting | Bristol-Myers Squibb | 362 | 2026-01-15 | 2026-04-29 | |
| A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China Mavacamten - Hypertrophic Cardiomyopathy | Recruiting | Bristol-Myers Squibb | 500 | 2026-01-15 | 2026-06-18 | |
| Myocardial Perfusion Changes Following Optimal Medical Treatment in Symptomatic Hypertrophic Cardiomyopathy Mavacamten in clinical routine use - Hypertrophic Obstructive Cardiomyopathy \(HOCM\) | Recruiting | Medical University of Vienna | 20 | 2025-09-05 | 2025-09-02 | |
| A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER) Mavacamten - Symptomatic Obstructive Hypertrophic Cardiomyopathy | Phase 4 | Active not recruiting | Bristol-Myers Squibb | 50 | 2025-09-04 | 2026-04-28 |
| Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan Mavacamten - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Recruiting | Bristol-Myers Squibb | 200 | 2025-05-21 | 2026-02-03 | |
| Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic Cardiomyopathy mavacamten - HCM - Hypertrophic Cardiomyopathy, Mavacamten | Not applicable | Active not recruiting | Xu Liu | 78 | 2025-04-20 | 2025-04-27 |
| Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy radiofrequency ablation, Mavacamten - Obstructive Hypertrophic Cardiomyopathy, Mavacamten | Not applicable | Not yet recruiting | Shanghai Chest Hospital | 40 | 2025-02-26 | 2025-03-04 |
| A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Mavacamten - Obstructive Hypertrophic Cardiomyopathy | Recruiting | Bristol-Myers Squibb | 600 | 2024-07-24 | 2024-11-06 | |
| Real-World Effectiveness of Mavacamten in Canada Mavacamten - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Completed | Bristol-Myers Squibb | 115 | 2024-06-24 | 2025-12-04 | |
| Real-world Patient Reported Outcomes Among Patients Treated With Camzyos Mavacamten - Obstructive Hypertrophic Cardiomyopathy | Recruiting | Bristol-Myers Squibb | 118 | 2024-05-10 | 2024-11-07 | |
| A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada Mavacamten - Hypertrophic Cardiomyopathy | Completed | Bristol-Myers Squibb | 683 | 2024-04-20 | 2026-06-12 | |
| A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy Mavacamten, Placebo - Cardiomyopathy, Hypertrophic | Phase 3 | Active not recruiting | Bristol-Myers Squibb | 44 | 2024-04-17 | 2025-12-19 |
| A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy Mavacamten - Cardiomyopathy, Hypertrophic | Phase 4 | Active not recruiting | Bristol-Myers Squibb | 63 | 2024-01-24 | 2026-09-16 |
| Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy mavacamten - Hypertrophic Cardiomyopathy (HCM), Obstructive Hypertrophic Cardiomyopathy (oHCM) | Completed | Chinese Academy of Medical Sciences, Fuwai Hospital | 222 | 2024-01-01 | 2026-04-17 | |
| A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US Mavacamten - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Active not recruiting | Bristol-Myers Squibb | 150 | 2023-12-22 | 2026-09-30 |
Showing 20 of 43. Sign in to see all of them.
Cardiomyopathy, Hypertrophic (37) · Ventricular Outflow Obstruction, Left (4) · Cardiomyopathies (2) · Anthrax (1) · Breast Feeding (1) · Cardiomyopathy, Familial Restrictive, 3 (1) · Cardiovascular Diseases (1) · Coronary Artery Disease (1) · Heart Diseases (1) · Heart Failure (1) · Hypertrophy (1)
Bristol-Myers Squibb (27) · MyoKardia, Inc. (6) · LianBio LLC (2) · Chinese Academy of Medical Sciences, Fuwai Hospital (1) · Medical University of Vienna (1) · Michael Ayers (1) · Second Affiliated Hospital of Nanchang University (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Shanghai Chest Hospital (1) · University of Manchester (1) · Xu Liu (1)
United States (22) · United Kingdom (9) · China (8) · Canada (6) · France (5) · Germany (5) · Spain (5) · Australia (4) · Czechia (4) · Italy (4) · Japan (4) · Poland (4) · Austria (3) · Belgium (3) · Denmark (3)
Jonathan C Fox, MD, PhD (2) · Amy Sehnert, MD (1) · Andrew Crean, BSc BM MRCP FRCR MPhil MPH (1) · Jing Zhang, Doctor (1) · Michael Grimm, MD (1) · Shuyang Zhang, M.D., Ph.D. (1)
PMID 42636950, PMID 39217450, PMID 31035291, PMID 32466879, PMID 32498620, PMID 32871100, PMID 34004177, PMID 34018809, PMID 34038706, PMID 34081217, PMID 34907813, PMID 34915982, PMID 35718845, PMID 35798455, PMID 35902155, PMID 36335531, PMID 36335645, PMID 36652223, PMID 37336533, PMID 37639243, PMID 37639259, PMID 37855754, PMID 37961906, PMID 38176782, PMID 38591260, PMID 38625800, PMID 38695527, PMID 38926266, PMID 39014868, PMID 39221824, PMID 39254622, PMID 39347697, PMID 39349158, PMID 39349160, PMID 39495835, PMID 39556124, PMID 39653325, PMID 39909647, PMID 40299193, PMID 40425241, PMID 40632050, PMID 40864018, PMID 40888717, PMID 41038603, PMID 41212168, PMID 41910394, PMID 42165935, PMID 42179278, PMID 42251960, PMID 42327436
2023 (2)